TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05288322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mostafa Maged maneuver
Description: The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus .
Study: NCT05429502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered at the RP2D defined from Phase I-Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered at the RP2D defined from Phase I-Part A.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribociclib
Description: Ribociclib administered at the RP2D defined from Phase I-Part A.
Study: NCT05537948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 inhibitor
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months.
Study: NCT06298331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Massage
Description: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
Study: NCT04850118

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAAV2tYF-GRK1-hRPGRco
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAAV2tYF-GRK1-hRPGRco
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: Untreated Control Group 3
Study: NCT06469216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
Study: NCT05936580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq
Description: Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Study: NCT06065657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Supplement
Description: Ketone supplement 3x day with control diet for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Control Diet breakfast, lunch, and dinner for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Control Diet breakfast, lunch, and dinner for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic Diet breakfast, lunch, and dinner for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Study: NCT05583721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]NH3
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]NH3
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]NH3
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given IV prior to PET stress test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given IV prior to PET stress test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given IV prior to PET stress test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
Study: NCT05687500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics study
Description: 0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-peptide proinsulin ratio
Description: blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood glucose on fluorinated tube
Description: 0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine biological monitoring
Description: If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glycose holter monitor
Description: glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
Study: NCT05696626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene in combination with abemaciclib
Description: 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant in combination with abemaciclib
Description: Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Study: NCT06565780

Intervention type: DEVICE
Group type: OTHER
Intervention: Device under test evaluation against references
Description: Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate.
Study: NCT04933539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
Study: NCT04758624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
Study: NCT06569056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8427
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem and Cilastatin Sodium
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRS-8427 placebo
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem and Cilastatin Sodium placebo
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study: NCT05814055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-free kava
Description: Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
Study: NCT06075667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06538116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mevidalen
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mevidalen
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05724563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
Study: NCT06025578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986278 Placebo
Description: Specified dose on specified days
Study: NCT06317285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3915393
Description: GSK3915393 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06536491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-104 high dose
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-104 low dose
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant
Description: Marketed product intravitreal injection
Study: NCT06355440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Navigation
Description: One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
Study: NCT05503017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-social, computerized intervention targeting error sensitivity
Description: The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-social, computerized intervention on healthy lifestyle choices
Description: The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
Study: NCT05415462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra
Description: Sterile suspension for injection
Study: NCT06384027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
Study: NCT06085547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
Study: NCT05989204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmCD19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmCD19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmCD19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmCD19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study: NCT06085547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural-Targeted SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.